IRHYTHM HOLDINGS INC

IRTC is the ticker for iRhythm Technologies, a medical device company focused on cardiac monitoring. Its core product, the Zio patch, is a wearable biosensor used to detect irregular heart rhythms such as atrial fibrillation. IRTC also offers data analytics and reporting services that help physicians diagnose and manage arrhythmias, addressing a large and growing market for ambulatory cardiac monitoring.

IRTC shares can react to a range of factors, including quarterly revenue and margin trends, reimbursement decisions by insurers such as Medicare, regulatory clearances for new products, and competitive dynamics in cardiac monitoring. Changes in clinical adoption, sales force productivity, and guidance updates can also influence sentiment. Broader market or sector rotations may amplify price moves given the stock's growth profile.

The 52-week range reflects the lowest and highest prices at which IRTC traded over the past year. This range is a useful reference for understanding recent volatility and where the current price sits relative to that band. For the most up-to-date 52-week high and low, please refer to the latest IRTC data displayed on this page.

Valuation for IRTC often relies on forward-looking metrics because the company may prioritize growth over near-term earnings. Investors commonly examine enterprise value-to-revenue, price-to-sales, and discounted cash flow models, while also considering gross margin trends, reimbursement expansion, and the path to profitability. Comparing these metrics with peers in medical devices can provide context, but growth assumptions heavily influence the outcome.

IRTC can trade in pre-market and after-hours sessions on U.S. exchanges, though liquidity is typically thinner and spreads may be wider than during regular trading. Extended-hours trading is available through many brokers but carries additional risks, including reduced volume and greater price volatility. Availability depends on your brokerage and the specific session.

IRTC has not historically paid a cash dividend. As a growth-oriented medical device company, it has generally retained earnings to fund product development, clinical trials, and commercial expansion. Whether that policy changes depends on future profitability, cash flow, and strategic priorities. For the latest dividend status, check the IRTC data shown on this page.